Topics

Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck

10:53 EST 4 Dec 2019 | Xconomy

A Roche immunotherapy has won an additional FDA approval as a first-line treatment for non-small lung cancer, bolstering the product’s competitive stance versus one from Merck. The FDA approved atezolizumab (Tecentriq) for adults whose non-squamous non-small cell lung cancer (NSCLC) is metastatic, meaning it has spread, and does not have the EGFR or ALK genetic […]

Original Article: Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck

NEXT ARTICLE

More From BioPortfolio on "Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck"

Quick Search

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...